Sanfilippo Syndrome: Optimizing Care with a Multidisciplinary Approach

References

• Benetó N, Vilageliu L, Grinberg D, Canals I. Sanfilippo syndrome: molecular basis, disease models and therapeutic approaches. Int J Mol Sci. 2020;21(21):7819. doi:10.3390/ijms21217819
   PubMed Web of Science ®Google Scholar
• Pierzynowska K, Rintz E, Gaffke L, et al. Mucopolysaccharidosis type III (Sanfilippo disease) subtypes A, B, C, D: molecular mechanism and therapeutic effect. In: Surendran S, editor. Neurochemistry of Metabolic Diseases - Lysosomal Storage Diseases, Phenylketonuria and Canavan Disease. Hauppauge NY, USA: Nova Science Publishers, Inc; 2020:51–101.
   Google Scholar
• Spahiu L, Behluli E, Peterlin B, et al. Mucopolysaccharidosis III: molecular basis and treatment. Pediatr Endocrinol Diabetes Metab. 2021;27:201–208. doi:10.5114/pedm.2021.109270
   PubMedGoogle Scholar
• Kaczor-Kamińska M, Kamiński K, Wróbel M. Heparan sulfate, Mucopolysaccharidosis IIIB and sulfur metabolism disorders. Antioxidants. 2022;11:678. doi:10.3390/antiox11040678
   Web of Science ®Google Scholar
• Fedele AO. Sanfilippo syndrome: causes, consequences, and treatments. Appl Clin Genet. 2015;8:269–281. doi:10.2147/TACG.S57672
   PubMedGoogle Scholar
• Węgrzyn G, Pierzynowska K, Pavone LM. Editorial: molecular aspects of Mucopolysaccharidoses. Front Mol Biosci. 2022;9:874267. doi:10.3389/fmolb.2022.874267
   PubMed Web of Science ®Google Scholar
• Wiśniewska K, Wolski J, Gaffke L, Cyske Z, Pierzynowska K, Węgrzyn G. Misdiagnosis in mucopolysaccharidoses. J Appl Genet. 2022;63:475–495. doi:10.1007/s13353-022-00703-1
   PubMed Web of Science ®Google Scholar
• Kowalewski B, Lamanna WC, Lawrence R, et al. Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice. Proc Natl Acad Sci U S A. 2012;109:10310–10315. doi:10.1073/pnas.1202071109
   PubMed Web of Science ®Google Scholar
• Kowalewski B, Heimann P, Ortkras T, et al. Ataxia is the major neuropathological finding in arylsulfatase G-deficient mice: similarities and dissimilarities to Sanfilippo disease (mucopolysaccharidosis type III). Hum Mol Genet. 2015;24:1856–1868. doi:10.1093/hmg/ddu603
   PubMed Web of Science ®Google Scholar
• Kruszewski K, Lüllmann-Rauch R, Dierks T, Bartsch U, Damme M. Degeneration of photoreceptor cells in arylsulfatase G-deficient mice. Invest Ophthalmol Vis Sci. 2016;57:1120–1131. doi:10.1167/iovs.15-17645
   PubMed Web of Science ®Google Scholar
• McBride KL, Flanigan KM. Update in the Mucopolysaccharidoses. Semin Pediatr Neurol. 2021;37:100874. doi:10.1016/j.spen.2021.100874
   PubMed Web of Science ®Google Scholar
• Nagpal R, Goyal RB, Priyadarshini K, et al. Mucopolysaccharidosis: a broad review. Indian J Ophthalmol. 2022;70:2249–2261. doi:10.4103/ijo.IJO_425_22
   PubMed Web of Science ®Google Scholar
• Kong W, Yao Y, Zhang J, Lu C, Ding Y, Meng Y. Update of treatment for mucopolysaccharidosis type III (Sanfilippo syndrome). Eur J Pharmacol. 2020;888:173562. doi:10.1016/j.ejphar.2020.173562
   PubMed Web of Science ®Google Scholar
• Seker Yilmaz B, Davison J, Jones SA, Baruteau J. Novel therapies for mucopolysaccharidosis type III. J Inherit Metab Dis. 2021;44(1):129–147. doi:10.1002/jimd.12316
   PubMed Web of Science ®Google Scholar
• Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020;9:1–9. doi:10.5582/irdr.2020.01011
   PubMed Web of Science ®Google Scholar
• Gaffke L, Pierzynowska K, Piotrowska E, Węgrzyn G. How close are we to therapies for Sanfilippo disease? Metab Brain Dis. 2018;33:1–10. doi:10.1007/s11011-017-0111-4
   PubMed Web of Science ®Google Scholar
• Rajan DS, Escolar ML. Evolving therapies in neuronopathic LSDs: opportunities and challenges. Metab Brain Dis. 2022. doi:10.1007/s11011-022-00939-0
   PubMed Web of Science ®Google Scholar
• Wijburg FA, Whitley CB, Muenzer J, et al. A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A. Mol Genet Metab. 2021;134:175–181. doi:10.1016/j.ymgme.2021.07.001
   PubMed Web of Science ®Google Scholar
• Wijburg FA, Heap F, Rust S, et al. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A. Mol Genet Metab. 2021;134:317–322. doi:10.1016/j.ymgme.2021.09.003
   PubMed Web of Science ®Google Scholar
• Deiva K, Ausseil J, de Bournonville S, et al. Intracerebral gene therapy in four children with Sanfilippo B syndrome: 5.5-year follow-up results. Hum Gene Ther. 2021;32:1251–1259. doi:10.1089/hum.2021.135
   PubMed Web of Science ®Google Scholar
• Ghosh A, Rust S, Langford-Smith K, et al. High dose genistein in Sanfilippo syndrome: a randomised controlled trial. J Inherit Metab Dis. 2021;44:1248–1262. doi:10.1002/jimd.12407
   PubMed Web of Science ®Google Scholar
• De Pasquale V, Pavone LM. Heparan sulfate proteoglycans: the sweet side of development turns sour in mucopolysaccharidoses. Biochim Biophys Acta Mol Basis Dis. 2019;1865:165539. doi:10.1016/j.bbadis.2019.165539
   PubMed Web of Science ®Google Scholar
• Węgrzyn G, Jakóbkiewicz-Banecka J, Narajczyk M, et al. Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different? Med Hypotheses. 2010;75:605–609. doi:10.1016/j.mehy.2010.07.044
   PubMed Web of Science ®Google Scholar
• Bruyère J, Roy E, Ausseil J, et al. Heparan sulfate saccharides modify focal adhesions: implication in mucopolysaccharidosis neuropathophysiology. J Mol Biol. 2015;427:775–791. doi:10.1016/j.jmb.2014.09.012
   PubMed Web of Science ®Google Scholar
• Trudel S, Trécherel E, Gomila C, et al. Oxidative stress is independent of inflammation in the neurodegenerative Sanfilippo syndrome type B. J Neurosci Res. 2015;93:424–432. doi:10.1002/jnr.23497
   PubMed Web of Science ®Google Scholar
• Pierzynowska K, Gaffke L, Cyske Z, et al. Oxidative Stress in Mucopolysaccharidoses: pharmacological Implications. Molecules. 2021;26:5616. doi:10.3390/molecules26185616
   PubMed Web of Science ®Google Scholar
• De Pasquale V, Moles A, Pavone LM. Cathepsins in the pathophysiology of mucopolysaccharidoses: new perspectives for therapy. Cells. 2020;9:979. doi:10.3390/cells9040979
   PubMed Web of Science ®Google Scholar
• Lamanna WC, Lawrence R, Sarrazin S, Esko JD. Secondary storage of dermatan sulfate in Sanfilippo disease. J Biol Chem. 2011;286:6955–6962. doi:10.1074/jbc.M110.192062
   PubMed Web of Science ®Google Scholar
• Dawson G, Fuller M, Helmsley KM, Hopwood JJ. Abnormal gangliosides are localized in lipid rafts in Sanfilippo (MPS3a) mouse brain. Neurochem Res. 2012;37:1372–1380. doi:10.1007/s11064-012-0761-x
   PubMed Web of Science ®Google Scholar
• Baydakova G, Ilyushkina A, Gaffke L, et al. Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses. Diagnostics. 2020;10:155. doi:10.3390/diagnostics10030155
   Web of Science ®Google Scholar
• Gaffke L, Pierzynowska K, Podlacha M, Brokowska J, Węgrzyn G. Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases. Cell Biol Int. 2021;45:498–506. doi:10.1002/cbin.11275
   PubMed Web of Science ®Google Scholar
• Gaffke L, Pierzynowska K, Podlacha M, et al. Underestimated Aspect of Mucopolysaccharidosis Pathogenesis: global Changes in Cellular Processes Revealed by Transcriptomic Studies. Int J Mol Sci. 2020;21:1204. doi:10.3390/ijms21041204
   PubMed Web of Science ®Google Scholar
• Gaffke L, Pierzynowska K, Rintz E, Cyske Z, Giecewicz I, Węgrzyn G. Gene Expression-Related Changes in Morphologies of Organelles and Cellular Component Organization in Mucopolysaccharidoses. Int J Mol Sci. 2021;22:2766. doi:10.3390/ijms22052766
   PubMed Web of Science ®Google Scholar
• Gaffke L, Pierzynowska K, Krzelowska K, Piotrowska E, Węgrzyn G. Changes in expressions of genes involved in the regulation of cellular processes in mucopolysaccharidoses as assessed by fibroblast culture-based transcriptomic analyses. Metab Brain Dis. 2020;35:1353–1360. doi:10.1007/s11011-020-00614-2
   PubMed Web of Science ®Google Scholar
• Brokowska J, Pierzynowska K, Gaffke L, Rintz E, Węgrzyn G. Expression of genes involved in apoptosis is dysregulated in mucopolysaccharidoses as revealed by pilot transcriptomic analyses. Cell Biol Int. 2021;45:549–557. doi:10.1002/cbin.11332
   PubMed Web of Science ®Google Scholar
• Rintz E, Gaffke L, Podlacha M, et al. Transcriptomic changes related to cellular processes with particular emphasis on cell activation in lysosomal storage diseases from the group of Mucopolysaccharidoses. Int J Mol Sci. 2020;21:3194. doi:10.3390/ijms21093194
   PubMed Web of Science ®Google Scholar
• Pierzynowska K, Gaffke L, Jankowska E, et al. Proteasome composition and activity changes in cultured fibroblasts derived from Mucopolysaccharidoses patients and their modulation by genistein. Front Cell Dev Biol. 2020;8:540726. doi:10.3389/fcell.2020.540726
   PubMed Web of Science ®Google Scholar
• Gaffke L, Szczudło Z, Podlacha M, et al. Impaired ion homeostasis as a possible associate factor in mucopolysaccharidosis pathogenesis: transcriptomic, cellular and animal studies. Metab Brain Dis. 2022;37:299–310. doi:10.1007/s11011-021-00892-4
   PubMed Web of Science ®Google Scholar
• Pierzynowska K, Żabińska M, Gaffke L, Cyske Z, Węgrzyn G. Changes in expression of signal transduction-related genes, and formation of aggregates of GPER1 and OXTR receptors in mucopolysaccharidosis cells. Eur J Cell Biol. 2022;101:151232. doi:10.1016/j.ejcb.2022.151232
   PubMed Web of Science ®Google Scholar
• Brokowska J, Gaffke L, Pierzynowska K, Cyske Z, Węgrzyn G. Cell cycle disturbances in mucopolysaccharidoses: transcriptomic and experimental studies on cellular models. Exp Biol Med. 2022. doi:10.1177/15353702221114872
   Web of Science ®Google Scholar
• Pierzynowska K, Gaffke L, Podlacha M, Węgrzyn G. Genetic base of behavioral disorders in Mucopolysaccharidoses: transcriptomic studies. Int J Mol Sci. 2020;21:1156. doi:10.3390/ijms21031156
   PubMed Web of Science ®Google Scholar
• Cyske Z, Gaffke L, Pierzynowska K, Węgrzyn G. Complex changes in the efficiency of the expression of many genes in monogenic diseases, Mucopolysaccharidoses, may arise from significant disturbances in the levels of factors involved in the gene expression regulation processes. Genes. 2022;13:593. doi:10.3390/genes13040593
   PubMed Web of Science ®Google Scholar
• Gómez-Pinilla F, Vu L, Cotman CW. Regulation of astrocyte proliferation by FGF-2 and heparan sulfate in vivo. J Neurosci. 1995;15:2021–2029. doi:10.1523/JNEUROSCI.15-03-02021.1995
   PubMed Web of Science ®Google Scholar
• Lemonnier T, Blanchard S, Toli D, et al. Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells. Hum Mol Genet. 2011;20:3653–3666. doi:10.1093/hmg/ddr285
   PubMed Web of Science ®Google Scholar
• Li HH, Zhao HZ, Neufeld EF, Cai Y, Gomez-Pinilla F. Attenuated plasticity in neurons and astrocytes in the mouse model of Sanfilippo syndrome type B. J Neurosci Res. 2002;69:30–38. doi:10.1002/jnr.10278
   PubMed Web of Science ®Google Scholar
• Pierzynowska K, Gaffke L, Podlacha M, Brokowska J, Węgrzyn G. Mucopolysaccharidosis and autophagy: controversies on the contribution of the process to the pathogenesis and possible therapeutic applications. Neuromolecular Med. 2020;22:25–30. doi:10.1007/s12017-019-08559-1
   PubMed Web of Science ®Google Scholar
• Pierzynowska K, Rintz E, Gaffke L, Węgrzyn G. Ferroptosis and its modulation by autophagy in light of the pathogenesis of lysosomal storage diseases. Cells. 2021;10:365. doi:10.3390/cells10020365
   PubMed Web of Science ®Google Scholar
• Bigger BW, Begley DJ, Virgintino D, Pshezhetsky AV. Anatomical changes and pathophysiology of the brain in mucopolysaccharidosis disorders. Mol Genet Metab. 2018;125:322–331. doi:10.1016/j.ymgme.2018.08.003
   PubMed Web of Science ®Google Scholar
• Heon-Roberts R, Nguyen ALA, Pshezhetsky AV. Molecular bases of neurodegeneration and cognitive decline, the major burden of Sanfilippo disease. J Clin Med. 2020;9:344. doi:10.3390/jcm9020344
   PubMed Web of Science ®Google Scholar
• Zhao HG, Aronovich EL, Whitley CB. Genotype-phenotype correspondence in Sanfilippo syndrome type B. Am J Hum Genet. 1998;62:53–63. doi:10.1086/301682
   PubMed Web of Science ®Google Scholar
• Di Natale P, Villani GR, Di Domenico C, Daniele A, Dionisi Vici C, Bartuli A. Analysis of Sanfilippo A gene mutations in a large pedigree. Clin Genet. 2003;63:314–318. doi:10.1034/j.1399-0004.2003.00053.x
   PubMed Web of Science ®Google Scholar
• Jansen AC, Cao H, Kaplan P, et al. Sanfilippo syndrome type D: natural history and identification of 3 novel mutations in the GNS Gene. Arch Neurol. 2007;64:1629–1634. doi:10.1001/archneur.64.11.1629
   PubMedGoogle Scholar
• Valstar MJ, Neijs S, Bruggenwirth HT, et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol. 2010;68:876–887. doi:10.1002/ana.22092
   PubMed Web of Science ®Google Scholar
• Héron B, Mikaeloff Y, Froissart R, et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet A. 2011;155A:58–68. doi:10.1002/ajmg.a.33779
   PubMed Web of Science ®Google Scholar
• Delgadillo V, O’Callaghan Mdel M, Gort L, Coll MJ, Pineda M. Natural history of Sanfilippo syndrome in Spain. Orphanet J Rare Dis. 2013;8:189. doi:10.1186/1750-1172-8-189
   PubMed Web of Science ®Google Scholar
• Pierzynowska K, Mański A, Limanówka M, et al. Untypically mild phenotype of a patient suffering from Sanfilippo syndrome B with the c.638C>T/c.889C>T (p.Pro213Leu/p.Arg297Ter) mutations in the NAGLU gene. Mol Genet Genomic Med. 2020;8(9):e1356. doi:10.1002/mgg3.1356
   PubMed Web of Science ®Google Scholar
• Lorenz D, Musacchio T, Kunstmann E, et al. A case report of Sanfilippo syndrome - the long way to diagnosis. BMC Neurol. 2022;22:93. doi:10.1186/s12883-022-02611-7
   PubMed Web of Science ®Google Scholar
• Anikiej-Wiczenbach P, Mański A, Milska-Musa K, et al. Highly diverse phenotypes of mucopolysaccharidosis type IIIB sibling patients: effects of an additional mutation in the AUTS2 gene. J Appl Genet. 2022. doi:10.1007/s13353-022-00702-2
   PubMed Web of Science ®Google Scholar
• Kong W, Lu C, Ding Y, Meng Y. Molecular environment and atypical function: what do we know about enzymes associated with Mucopolysaccharidoses? Orphanet J Rare Dis. 2022;17:112. doi:10.1186/s13023-022-02211-1
   PubMed Web of Science ®Google Scholar
• Perkins KJ, Muller V, Weber B, Hopwood JJ. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients. Mol Genet Metab. 2001;73:306–312. doi:10.1006/mgme.2001.3190
   PubMed Web of Science ®Google Scholar
• Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymańska A, Czartoryska B, Wegrzyn A, Wegrzyn G. Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Acta Paediatr. 2009;98:743–749. doi:10.1111/j.1651-2227.2008.01153.x
   PubMed Web of Science ®Google Scholar
• Jakobkiewicz-Banecka J, Gabig-Ciminska M, Kloska A, et al. Glycosaminoglycans and mucopolysaccharidosis type III. Front Biosci. 2016;21:1393–1409. doi:10.2741/4463
   Web of Science ®Google Scholar
• Bodamer OA, Giugliani R, Wood T. The laboratory diagnosis of mucopolysaccharidosis III (Sanfilippo syndrome): a changing landscape. Mol Genet Metab. 2014;113:34–41. doi:10.1016/j.ymgme.2014.07.013
   PubMed Web of Science ®Google Scholar
• Wijburg FA, Węgrzyn G, Burton BK, Tylki-Szymańska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr. 2013;102:462–470. doi:10.1111/apa.12169
   PubMed Web of Science ®Google Scholar
• Andrade F, Aldámiz-Echevarría L, Llarena M, Couce ML. Sanfilippo syndrome: overall review. Pediatr Int. 2015;57:331–338. doi:10.1111/ped.12636
   PubMed Web of Science ®Google Scholar
• Wolfenden C, Wittkowski A, Hare DJ. Symptoms of autism spectrum disorder (ASD) in individuals with Mucopolysaccharide disease type III (Sanfilippo Syndrome): a systematic review. J Autism Dev Disord. 2017;47:3620–3633. doi:10.1007/s10803-017-3262-6
   PubMed Web of Science ®Google Scholar
• Anikiej-Wiczenbach P, Rudnik A, Limanówka M, Wierzba J, Mański A. Diagnosis of children with Sanfilippo disease—Psychological, social and motor assessment. Acta Neuropsychol. 2020;18:525–535. doi:10.5604/01.3001.0014.5316
   Web of Science ®Google Scholar
• Urgancı N, Kalyoncu D, Gümüştekin R. Is mucopolysaccharidosis a cause of sleep and speech disorders? Report of four cases. J Acad Res Med. 2020;10:204–207. doi:10.4274/jarem.galenos.2020.3255
   Web of Science ®Google Scholar
• Escolar M, Bradshaw J, Tharp Byers V, et al. Development of a clinical algorithm for the early diagnosis of Mucopolysaccharidosis III. J Inborn Errors Metabol Screening. 2020;8:2. doi:10.1590/2326-4594-JIEMS-2020-0002
   Google Scholar
• Cimaz R, Coppa GV, Koné-Paut I, et al. Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis. Pediatr Rheumatol Online J. 2009;7:18. doi:10.1186/1546-0096-7-18
   PubMed Web of Science ®Google Scholar
• Ahmed M, Saleem A, Nasir S, Ariff M, Iftikhar P. Landau-Kleffner syndrome: a diagnostic challenge. Cureus. 2020;12:e7182. doi:10.7759/cureus.7182
   PubMed Web of Science ®Google Scholar
• Rezayi A, Feshangchi-Bonab M, Taherian R. An uncommon presentation of Mucopolysaccharidosis type IIIb similar to the Landau-Kleffner syndrome. Iran J Child Neurol. 2019;13:105–111. doi:10.22037/ijcn.v13i3.16536
   PubMed Web of Science ®Google Scholar
• Zeng Q, Fan Y, Wang L, Huang Z, Gu X, Yu Y. Molecular defects identified by whole exome sequencing in a child with atypical mucopolysaccharidosis IIIB. J Pediatr Endocrinol Metab. 2017;30:463–469. doi:10.1515/jpem-2016-0333
   PubMed Web of Science ®Google Scholar
• Shapiro EG, Eisengart JB. The natural history of neurocognition in MPS disorders: a review. Mol Genet Metab. 2021;133:8–34. doi:10.1016/j.ymgme.2021.03.002
   PubMed Web of Science ®Google Scholar
• Wagner VF, Northrup H, et al. Mucopolysaccharidosis Type III. In: Adam MP, Mirzaa GM, Pagon RA, editors. GeneReviews^®. Seattle: University of Washington, Seattle; 2019.
   Google Scholar
• Kalkan Ucar S, Ozbaran B, Demiral N, Yuncu Z, Erermis S, Coker M. Clinical overview of children with mucopolysaccharidosis type IIIA and effect of Risperidone treatment on children and their mothers psychological status. Brain Dev. 2010;32:156–161.
   PubMed Web of Science ®Google Scholar
• Mahon LV, Lomax M, Grant S, et al. Assessment of sleep in children with mucopolysaccharidosis type III. PLoS One. 2014;9:e84128. doi:10.1371/journal.pone.0084128
   PubMed Web of Science ®Google Scholar
• Nur BG, Nur H, Mihci E. Bone mineral density in patients with mucopolysaccharidosis type III. J Bone Miner Metab. 2017;35:338–343. doi:10.1007/s00774-016-0762-y
   PubMed Web of Science ®Google Scholar
• Cohen MA, Stuart GM. Delivery of anesthesia for children with Mucopolysaccharidosis Type III (Sanfilippo syndrome): a review of 86 anesthetics. Paediatr Anaesth. 2017;27:363–369. doi:10.1111/pan.13075
   PubMed Web of Science ®Google Scholar
• Clark BM, Sprung J, Weingarten TN, Warner ME. Anesthesia for patients with mucopolysaccharidoses: comprehensive review of the literature with emphasis on airway management. Bosn J Basic Med Sci. 2018;18:1–7. doi:10.17305/bjbms.2017.2201
   PubMed Web of Science ®Google Scholar
• Murgasova L, Jurovcik M, Jesina P, et al. Otorhinolaryngological manifestations in 61 patients with mucopolysaccharidosis. Int J Pediatr Otorhinolaryngol. 2020;135:110137. doi:10.1016/j.ijporl.2020.110137
   PubMed Web of Science ®Google Scholar
• Nijmeijer SCM, de Bruin-Bon RHACM, Wijburg FA, Kuipers IM. Cardiac disease in mucopolysaccharidosis type III. J Inherit Metab Dis. 2019;42:276–285. doi:10.1002/jimd.12015
   PubMed Web of Science ®Google Scholar
• Lin HY, Chen MR, Lin SM, et al. Cardiac characteristics and natural progression in Taiwanese patients with mucopolysaccharidosis III. Orphanet J Rare Dis. 2019;14:140. doi:10.1186/s13023-019-1112-7
   PubMed Web of Science ®Google Scholar
• De Pasquale V, Pezone A, Sarogni P, et al. EGFR activation triggers cellular hypertrophy and lysosomal disease in NAGLU-depleted cardiomyoblasts, mimicking the hallmarks of mucopolysaccharidosis IIIB. Cell Death Dis. 2018;9:40. doi:10.1038/s41419-017-0187-0
   PubMed Web of Science ®Google Scholar
• Schiattarella GG, Cerulo G, De Pasquale V, et al. The murine model of mucopolysaccharidosis IIIB develops cardiopathies over time leading to heart failure. PLoS One. 2015;10:e0131662. doi:10.1371/journal.pone.0131662
   PubMed Web of Science ®Google Scholar
• Thomas S, Ramaswami U, Cleary M, Yaqub M, Raebel EM. Gastrointestinal manifestations in Mucopolysaccharidosis Type III: review of death certificates and the literature. J Clin Med. 2021;10:4445. doi:10.3390/jcm10194445
   PubMed Web of Science ®Google Scholar
• Wegrzyn G, Kurlenda J, Liberek A, et al. Atypical microbial infections of digestive tract may contribute to diarrhea in mucopolysaccharidosis patients: a MPS I case study. BMC Pediatr. 2005;5:9. doi:10.1186/1471-2431-5-9
   PubMedGoogle Scholar
• Valstar MJ, Marchal JP, Grootenhuis M, Colland V, Wijburg FA. Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome). Orphanet J Rare Dis. 2011;6:43. doi:10.1186/1750-1172-6-43
   PubMed Web of Science ®Google Scholar
• Cross EM, Hare DJ. Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders. J Inherit Metab Dis. 2013;36:189–200. doi:10.1007/s10545-012-9572-0
   PubMed Web of Science ®Google Scholar
• Hartley T, Lemire G, Kernohan KD, Howley HE, Adams DR, Boycott KM. New diagnostic approaches for undiagnosed rare genetic diseases. Annu Rev Genomics Hum Genet. 2020;21:351–372. doi:10.1146/annurev-genom-083118-015345
   PubMed Web of Science ®Google Scholar
• Cuzzocrea F, Larcan R, Westh F. Family and parental functioning in parents of disabled children. Nordic Psychology. 2013;65:271–287. doi:10.1080/19012276.2013.824201
   Web of Science ®Google Scholar
• Walker A, Alfonso ML, Colquitt G, Weeks K, Telfair J. “When everything changes:” Parent perspectives on the challenges of accessing care for a child with a disability. Disabil Health J. 2016;9:157–161. doi:10.1016/j.dhjo.2015.06.002
   PubMed Web of Science ®Google Scholar
• Cross EM, Grant S, Jones S, et al. An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III. J Neurodev Disord. 2014;6:46. doi:10.1186/1866-1955-6-46
   PubMed Web of Science ®Google Scholar
• Congedi S, Orzalesi M, Di Pede C, Benini F. Pain in Mucopolysaccharidoses: analysis of the Problem and Possible Treatments. Int J Mol Sci. 2018;19:3063. doi:10.3390/ijms19103063
   PubMed Web of Science ®Google Scholar
• Porter KA, O’Neill C, Drake E, et al. Caregivers’ assessment of meaningful and relevant clinical outcome assessments for Sanfilippo syndrome. J Patient Rep Outcomes. 2022;6:40. doi:10.1186/s41687-022-00447-w
   PubMedGoogle Scholar
• Shapiro E, Ahmed A, Whitley C, Delaney K. Observing the advanced disease course in mucopolysaccharidosis, type IIIA; a case series. Mol Genet Metab. 2018;123:123–126. doi:10.1016/j.ymgme.2017.11.014
   PubMed Web of Science ®Google Scholar
• Grant S, Cross E, Wraith JE, et al. Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID). J Inherit Metab Dis. 2013;36:281–291. doi:10.1007/s10545-012-9558-y
   PubMed Web of Science ®Google Scholar
• Conijn T, Nijmeijer SCM, van Oers HA, Wijburg FA, Haverman L. Psychosocial functioning in parents of MPS III patients. JIMD Rep. 2019;44:33–41. doi:10.1007/8904_2018_119
   PubMedGoogle Scholar